Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 6/20 | 0.66 |
| ▸ | MAPT | P10636 | 3/20 | 0.66 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.66 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.66 |
| ▸ | NPC1 | O15118 | 5/20 | 0.63 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.58 |
| ▸ | MEN1 | O00255 | 2/20 | 0.58 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.58 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.58 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.58 |
| ▸ | POLB | P06746 | 3/20 | 0.57 |
| ▸ | HPGD | P15428 | 1/20 | 0.57 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.57 |
| ▸ | APEX1 | P27695 | 1/20 | 0.57 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.57 |
| ▸ | WNT3A | P56704 | 1/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2938583 | 0.88 | MEN1 (0.69) | RAB9AMAPTNPSR1PDE4DNPC1 | |
| SCHEMBL15153224 | 0.85 | RAB9A (0.74) | RAB9AMAPTNPSR1PDE4DNPC1 | |
| SCHEMBL9779069 | 0.85 | CYP1A2 (0.56) | RAB9AMAPTNPSR1PDE4DNPC1 | |
| SCHEMBL28524227 | 0.85 | RAB9A (0.64) | RAB9AMAPTNPSR1PDE4DNPC1 | |
| SCHEMBL2937866 | 0.85 | RAB9A (0.64) | RAB9AMAPTNPSR1PDE4DNPC1 | |
| SCHEMBL11110984 | 0.83 | CYP1A2 (0.55) | RAB9AMAPTNPSR1PDE4DNPC1 | |
| SCHEMBL8031114 | 0.82 | RAB9A (0.61) | RAB9AMAPTNPSR1PDE4DNPC1 | |
| SCHEMBL6392543 | 0.81 | MEN1 (0.52) | RAB9AMAPTNPSR1PDE4DNPC1 | |
| SCHEMBL2559503 | 0.81 | PDE4D (0.56) | RAB9AMAPTNPSR1PDE4DNPC1 | |
| SCHEMBL5904628 | 0.80 | ATM (0.51) | RAB9AMAPTNPSR1PDE4DNPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9926282-B2 | Phthalazinones and isoquinolinones as rock inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2018-03-27 | — | — | US | disclosed |
| US-20150353505-A1 | PHTHALAZINONES AND ISOQUINOLINONES AS ROCK INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2015-12-10 | — | — | US | disclosed |
| US-8962551-B2 | Quinoxalinyl derivatives | ENANTA PHARMACEUTICALS, INC. (US) | 2015-02-24 | — | — | US | disclosed |
| US-8962551-B2 | Quinoxalinyl derivatives | ENANTA PHARMACEUTICALS, INC. (US) | 2015-02-24 | — | — | US | disclosed |
| US-20090180981-A1 | QUINOXALINYL DERIVATIVES | ENANTA PHARMACEUTICALS, INC. | 2009-07-16 | — | — | US | disclosed |
| US-20090180981-A1 | QUINOXALINYL DERIVATIVES | ENANTA PHARMACEUTICALS, INC. | 2009-07-16 | — | — | US | disclosed |
| WO-2009073719-A1 | QUINOXALINYL DERIVATIVES | ENANTA PHARMACEUTICALS, INC. (US) | 2009-06-11 | — | — | WO | disclosed |
| US-7511145-B2 | Bicyclic heteroaryl derivatives | GENELABS TECHNOLOGIES, INC. (US) | 2009-03-31 | — | — | US | disclosed |
| US-20090081165-A1 | BICYCLIC HETEROARYL DERIVATIVES | GENELABS TECHNOLOGIES, INC. | 2009-03-26 | — | — | US | disclosed |
| EP-1651631-A1 | BICYCLIC IMIDAZOL DERIVATIVES AGAINST FLAVIVIRIDAE | GENELABS TECHNOLOGIES, INC. (US) | 2006-05-03 | — | — | EP | disclosed |
| US-20050187390-A1 | Bicyclic heteroaryl derivatives | GENELABS TECHNOLOGIES, INC. | 2005-08-25 | — | — | US | disclosed |
| WO-2005012288-A1 | BICYCLIC IMIDAZOL DERIVATIVES AGAINST FLAVIVIRIDAE | GENELABS TECHNOLOGIES, INC (US) | 2005-02-10 | — | — | WO | disclosed |
| US-4325962-A | ANTIINFLAMMATORY AGENTS, ANALGESICS, ANTIDYRETICS | BYK-GULDEN LOMBERG CHEMISCHE FABRIK GMBH (DE) | 1982-04-20 | — | — | US | disclosed |
| US-4316815-A | OPTICAL BRIGHTENERS FOR POLYAMIDES, CELLULOSICS | SANDOZ LTD. (CH) | 1982-02-23 | — | — | US | disclosed |
| US-4146721-A | ANALGESICS, ANTIINFLAMMATORY AGENTS AND ANTIPYRETICS | BYK GULDEN LOMBERG CHEMISCHE FABRIK GMBH (DE) | 1979-03-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090180981-A1 | QUINOXALINYL DERIVATIVES | SQOR, ATG4A, NQO1 | RAB9A 2188/4885MAPT 4629/4885NPSR1 2470/4885 |
| US-20090081165-A1 | BICYCLIC HETEROARYL DERIVATIVES | HAVCR2, MAVS, ZC3HAV1 | RAB9A 893/4885MAPT 2748/4885NPSR1 4443/4885 |
| US-20150353505-A1 | PHTHALAZINONES AND ISOQUINOLINONES AS ROCK INHIBITORS | MYLK, MYLK2, ROCK1 | RAB9A 1244/4885MAPT 138/4885NPSR1 4084/4885 |
| US-20050187390-A1 | Bicyclic heteroaryl derivatives | HAVCR2, MAVS, ZC3HAV1 | RAB9A 893/4885MAPT 2748/4885NPSR1 4443/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.